Search

Displaying results 2551 - 2560 of 10000 in total
  1. Drug

    Atacicept

    go.drugbank.com/drugs/DB06399
    ApprovedInvestigational

    [L63797] Reducing BAFF- and APRIL-mediated signaling lowers production of galactose-deficient IgA1, an aberrant antibody whose deposition in the kidney drives IgA nephropathy. … [L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.

  2. Drug

    Paramethadione

    go.drugbank.com/drugs/DB00617
    Approved

    Paramethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.

  3. Drug

    Fursultiamine

    go.drugbank.com/drugs/DB08966
    Approved

    It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.

    Mixtures: ALINAMIN EX PLUS
  4. Drug

    Tromethamine

    go.drugbank.com/drugs/DB03754
    ApprovedInvestigational

    as an alkalizer. … It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Haloprogin

    go.drugbank.com/drugs/DB00793
    ApprovedWithdrawn

    Haloprogin is used as a topical ointment or cream in the treatment of Tinea infections. … Haloprogin is no longer available in the United States and has been discontinued.

  6. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    [L40533] Mitapivat has also been investigated in other hereditary red blood cell disorders associated with hemolytic anemia, such as sickle cell disease and alpha- and beta-thalassemia. … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

    Synonyms: Pkr-in-1
  7. Drug

    Fulzerasib

    go.drugbank.com/drugs/DB21609
    Investigational

    112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation). … The usage of the INN stem '-rasib' in the name indicates that Fulzerasib is a Ras protein inhibitor.

  8. Drug

    Phylloquinone

    go.drugbank.com/drugs/DB01022
    ApprovedInvestigational

    [L33319] Phylloquinone has been synthesized since at least 1939,[A234384] and was approved by the FDA prior to 1955.[L33389] … [A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity

    Mixtures: Vitalipid N, Vitalipid N
  9. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.

  10. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241030, A241040] Narsoplimab (OMS721), a human IgG4λ anti-MASP-2 antibody, is under consideration as a treatment for hematopoietic stem cell transplant-associated TMA (HSCT-TMA/TA-TMA) and IgA nephropathy … [A241030] Evidence increasingly points to a role for the complement system in TMA.

    Synonyms: IMMUNOGLOBULIN G4-LAMBDA, ANTI-(HOMO SAPIENS MANNAN-BINDING LECTIN SERINE PROTEASE 2 (MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASE 2, EC=3.4.21.104) HUMAN MONOCLONAL ANTIBODY .GAMMA.4 HEAVY CHAIN